eFFECTOR Therapeutics raises $45m in Series A
This article was originally published in Scrip
Executive Summary
San Diego-based eFFECTOR Therapeutics has raised $45 million in Series A venture capital to develop small molecules that selectively regulate protein synthesis – otherwise known as translation – and advance a cancer drug candidate into human trials within three years.